BIOSOLVE-II-III

Actions

 
 
24-month pooled analysis1
 
 Conclusions
  • Target Lesion Failure (TLF) and Target Lesion Revascularization (TLR) rates in BIOSOLVE-II and III remain low and comparable to 2nd generation drug-eluting stents out to 24 months
  • No definite or probable Scaffold Thrombosis (ST) were reported up to 24 months
 
 
Study design
Pooled analysis of BIOSOLVE-II and BIOSOLVE-III, two prospective clinical trials.
Endpoints
Primary endpoints
  • BIOSOLVE-II: In-segment LLL at 6-month follow-up
  • BIOSOLVE-III: Procedural success
Secondary endpoints (selected)
  • TLF defined as a composite of cardiac death, Target-Vessel Myocardial Infarction (MI) and Clinically-Driven Target Lesion Revascularization (CD-TLR) at 12 months
  • Definite/probable ST at 12 months
 
 
 
 

 

Principal investigators
 
Prof. M. Haude, Lukaskrankenhaus, Neuss, Germany
1. Haude M. Imaging and Clinical Results with the latest Magmaris Magnesium-Based Scaffold, presented at: TCT, September 22, San Diego, USA; 2. TLF defined as a composite of cardiac death, Target-Vessel Myocardial Infarction (TV MI) and Clinically-Driven Target Lesion Revascularization and CABG. All events have been adjudicated by a clinical events committee; 3. Peri-procedural MI according to SCAI definition and spontaneous MI according to the Extended Historical definition.
 

${loading}